CDA – Consultation on Proposed Improvements to the Reimbursement Review Process

Please visit https://www.cda-amc.ca/consultation-proposed-improvements-reimbursement-review-process for full information on this opportunity.

The drug Reimbursement Review process at Canada’s Drug Agency plays a critical role in the pathway that helps patients access new drugs. In June 2023, CDA signalled program improvements that could be explored or added to the process. Since that time, the organization has been engaging with all partners to identify additional improvements and new approaches.

The measures proposed in this consultation document are intended to accelerate patient access to proven new treatments and streamline our processes. CDA looks forward to receiving feedback on these proposals and moving toward thoughtful implementation after assessing the feedback. We are seeking feedback from interested parties on the following 6 topics:

  • proportionate review processes
  • review and recommendation reporting
  • deliberative process
  • accelerated access pathways
  • checkpoints with sponsors throughout the drug Reimbursement Review process
  • application requirements for sponsor submissions.

How to participate

To provide comments on the proposal, use the feedback template.

Feedback must be received by 5:00 p.m. ET on February 6, 2025. For feedback to be considered, individuals and organizations must be identified by name in the template. One response per organization will be considered.

Contact us

Questions about the feedback process can be sent to feedback@cda-amc.ca.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply